Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

Every Patient In This Bowel Cancer Trial Has Been Cancer Free For Nearly Three Years

In one of the most striking results from any cancer clinical trial in recent years, every single patient in a bowel cancer study has remained cancer-free for nearly three years after receiving a short course of immunotherapy before surgery, with zero relapses recorded in the entire cohort as of the latest follow-up data. The NEOPRISM-CRC trial, led by researchers at University College London and University College London Hospitals, gave patients with a specific form of stage two or three bowel cancer nine weeks of pre-operative treatment with the immunotherapy drug pembrolizumab, replacing the conventional approach of post-operative chemotherapy. Initial results showed that 59 percent of patients had no detectable cancer after the immunotherapy and surgery combined, and the new follow-up data at 33 months shows that not only have those patients remained clear, but even the patients who still had small amounts of cancer remaining after treatment saw none of it grow or spread. Under the standard treatment pathway, roughly 25 percent of similar patients would be expected to relapse within three years.

The results were presented at the American Association for Cancer Research Annual Meeting in April 2026 and have generated significant excitement among oncologists. The specific bowel cancer treated in the trial, known as mismatch repair-deficient cancer, affects roughly 15 percent of all bowel cancer patients and is characterized by genetic errors that make it particularly responsive to immunotherapy. Researchers noted that the results suggest a nine-week drug course could replace months of chemotherapy and provide more durable protection against recurrence, a potential shift in how this form of the disease is treated from the ground up. Scientists called the zero-relapse figure at nearly three years extraordinary, and said larger trials are now needed to confirm and extend the findings across wider patient populations.

Source: https://scitechdaily.com/breakthrough-bowel-cancer-trial-leaves-patients-cancer-free-for-nearly-3-years/

PrevPreviousColorado Just Banned Pet Store Dog And Cat Sales
NextA 12-Year-Old Fighting Brain Cancer Raised $22 At A Lemonade Stand For Research And Then Something Incredible HappenedNext

Recent Articles

Happy News

Pizza Huts 40-Year-Old Reading Program Is Back This Summer And Kids Can Earn Free Pizza

May 4, 2026

Pizza Hut’s beloved Book It program, which has been rewarding kids with free pizza for reading since 1984, is returning for summer with a new name and a new app just in time for the months when children are most at risk of losing their reading progress. The program, called

Read More
Happy News

This Chef Buttered 10 Slices Of Bread In 16 Seconds, A New World Record

May 3, 2026

Zeinab Bance is a chef and mother of three from Côte d’Ivoire, which means she knows her way around a kitchen. But on March 17, she took a task most people do on autopilot every morning and turned it into something extraordinary: she buttered 10 slices of bread in just

Read More
Happy News

A Canadian Tow Truck Driver Found A Moose Trapped In Ice And Said All His Other Jobs Could Wait

May 3, 2026

Clint Gottinger, a tow truck operator in Kelvington, Saskatchewan, was heading out to two jobs last Saturday evening when he spotted a yearling moose at a frozen junction near his home, exhausted and trapped in the ice, and made a decision that has since made him briefly famous across Canada:

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.